Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers

This study is currently recruiting participants.
Verified February 2013 by University Hospital, Ghent
Sponsor:
Collaborators:
Medtronic
Johnson & Johnson
Information provided by (Responsible Party):
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT00658983
First received: April 7, 2008
Last updated: February 1, 2013
Last verified: February 2013

April 7, 2008
February 1, 2013
April 2008
May 2013   (final data collection date for primary outcome measure)
Wound healing [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00658983 on ClinicalTrials.gov Archive Site
Wound healing [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers
Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers

Compare Autologous Platelet Enriched Gel versus Metalloproteinase Inhibitor in the healing of chronic lower leg ulcers.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Chronic Lower Leg Ulcer
  • Other: Autologous Platelet Enriched Gel
    Treatment with Autologous Platelet Enriched Gel
  • Other: Metalloproteinase Inhibitor
    Treatment with Metalloproteinase Inhibitor (Promogran)
  • Experimental: 1
    Autologous Platelet Enriched Gel
    Intervention: Other: Autologous Platelet Enriched Gel
  • Active Comparator: 2
    Metalloproteinase Inhibitor (Promogran)
    Intervention: Other: Metalloproteinase Inhibitor
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 year or older
  • A non-healing chronic lower leg ulcer
  • Platelet ranges of 150000 per ml circulating blood

Exclusion Criteria:

  • Presence of a tumor or metastatic disease
  • Hypersensitive to collagen regenerated cellulose
  • Hemodynamic unstable patient
  • Hypercoagulability
  • Heart decompensation or angina pectoris
Both
18 Years and older
No
Contact: Wim Bongaerts, MD +32 9 332 67 95 Willem.bongaerts@ugent.be
Belgium
 
NCT00658983
2008/049
No
University Hospital, Ghent
University Hospital, Ghent
  • Medtronic
  • Johnson & Johnson
Principal Investigator: Wim Bongaerts, MD University Hospital, Ghent
Principal Investigator: Wouter De Moor University Hospital, Ghent
University Hospital, Ghent
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP